Company intelligence / Profile preview

L&J Bio

Seongnam-si, Gyeonggi-do, South Korea

Ownership: Private
Development stage: Other

Overview

L&J Bio is a South Korean biotechnology company specializing in the development of Natural Killer (NK) cell therapies for oncology. The company utilizes a proprietary platform for the mass production and activation of high-purity NK cells, aiming to provide effective allogeneic treatments for solid tumors and hematologic malignancies. Their lead candidate, L&J-NK, is currently being evaluated in clinical trials for its safety and efficacy in patients with advanced cancers. L&J Bio maintains its own GMP manufacturing capabilities to ensure the quality and scalability of its cell therapy products.

Therapeutic areas: Oncology
Modalities: NK cell therapyCell therapy
Industry: Biotech

Drug pipeline

2 assets

L&J-HL

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on L&J Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on L&J Bio.

Explore the full profile